Comparison of oseltamivir and α-galactosylceramide for reducing disease and transmission in pigs infected with 2009 H1N1 pandemic influenza virus.

Autor:	Madrid DMC; Division of Animal Sciences, University of Missouri, Columbia, MO, United States., Gu W; Department of Animal Sciences, University of Florida, Gainesville, FL, United States., Artiaga BL; Department of Diagnostic Medicine and Pathobiology, College of Veterinary Medicine, Kansas State University, Manhattan, KS, United States., Yang G; Department of Infectious Diseases and Public Health, City University of Hong Kong, Hong Kong, Hong Kong SAR, China., Loeb J; Department of Environmental and Global Health, University of Florida, Gainesville, FL, United States.; Emerging Pathogens Institute, University of Florida, Gainesville, FL, United States., Hawkins IK; Department of Comparative, Diagnostic, and Population Medicine, University of Florida, Gainesville, FL, United States., Castleman WL; Department of Comparative, Diagnostic, and Population Medicine, University of Florida, Gainesville, FL, United States., Lednicky JA; Department of Environmental and Global Health, University of Florida, Gainesville, FL, United States.; Emerging Pathogens Institute, University of Florida, Gainesville, FL, United States., Richt JA; Department of Diagnostic Medicine and Pathobiology, College of Veterinary Medicine, Kansas State University, Manhattan, KS, United States., Driver JP; Division of Animal Sciences, University of Missouri, Columbia, MO, United States.
Jazyk:	angličtina
Zdroj:	Frontiers in veterinary science [Front Vet Sci] 2022 Oct 20; Vol. 9, pp. 999507. Date of Electronic Publication: 2022 Oct 20 (Print Publication: 2022).
DOI:	10.3389/fvets.2022.999507
Abstrakt:	Influenza virus infections are a major cause of respiratory disease in humans. Neuraminidase inhibitors (NAIs) are the primary antiviral medication used to treat ongoing influenza infections. However, NAIs are not always effective for controlling virus shedding and lung inflammation. Other concerns are the emergence of NAI-resistant virus strains and the risk of side effects, which are occasionally severe. Consequently, additional anti-influenza therapies to replace or combine with NAIs are desirable. Here, we compared the efficacy of the NAI oseltamivir with the invariant natural killer T (iNKT) cell superagonist, α-galactosylceramide (α-GalCer), which induces innate immune responses that inhibit influenza virus replication in mouse models. We show that oseltamivir reduced lung lesions and lowered virus titers in the upper respiratory tract of pigs infected with A/California/04/2009 (CA04) pandemic H1N1pdm09. It also reduced virus transmission to influenza-naïve contact pigs. In contrast, α-GalCer had no impact on virus replication, lung disease, or virus transmission, even when used in combination with oseltamivir. This is significant as iNKT-cell therapy has been studied as an approach for treating humans with influenza. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2022 Madrid, Gu, Artiaga, Yang, Loeb, Hawkins, Castleman, Lednicky, Richt and Driver.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu